Traditional Chinese medicine in synergy with conventional therapy improves renal outcomes and provides survival benefit in patients with systemic lupus erythematosus: a cohort study from the largest health care system in Taiwan.
{"title":"Traditional Chinese medicine in synergy with conventional therapy improves renal outcomes and provides survival benefit in patients with systemic lupus erythematosus: a cohort study from the largest health care system in Taiwan.","authors":"Chen-Ying Wei, Chiao-Hsuan Chu, Hsuan-Shu Shen, Po-Chuan Ko, Jiun-Liang Chen, Han-Hua Yu","doi":"10.1080/03007995.2025.2478160","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that significantly impacts renal function. Despite conventional treatments, morbidity and mortality remain high, necessitating the exploration of safer and more effective therapies, including the potential benefits of Traditional Chinese Medicine (TCM) for improving kidney health and survival rates.</p><p><strong>Methods: </strong>Patients with newly diagnosed SLE with catastrophic illness certificate were retrospectively enrolled from the Chang Gung Research Database (CGRD) between 2005 and 2020. Patients were stratified into groups based on TCM treatment post-diagnosis. Outcomes measured included end-stage renal disease (ESRD) incidence and all-cause mortality, using Cox proportional hazard models and Kaplan-Meier analysis for statistical evaluation.</p><p><strong>Results: </strong>Among 10,462 newly diagnosed SLE patients, 1,831 had received at least 28 days of TCM treatment, while 7,966 had not received TCM treatment. After propensity score matching, there were equally 1,831 individuals in each group, with no significant baseline differences in age, sex, biochemical profiles, or comorbidities. TCM usage was associated with a significantly reduced rate of ESRD over a 0.5-year follow-up (adjusted hazard ratio (aHR) = 0.24; 95% confidence interval (CI) = 0.07-0.80, <i>p</i> = .02), with a trend that persisted over 5 years. The TCM group's proteinuria was significantly lower than that of the non-TCM group at various time points post-index date, including 6 months (174.98 mg vs. 248.09 mg, <i>p</i> <.001), 1 year (161.05 mg vs. 303.03 mg, <i>p</i> <.001), 3 years (150.26 mg vs. 250 mg, <i>p</i> = .03), and 10 years (147.06 mg vs. 190.75 mg, <i>p</i> = .03). After adjusting for confounding covariates, TCM users had a significantly decreased risk of mortality (aHR = 0.70, 95% CI = 0.58-0.83).</p><p><strong>Conclusion: </strong>Integrating TCM with conventional treatment could lower risk of ESRD and mortality, highlighting the potential for a more holistic approach to patient care for SLE.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"559-567"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2478160","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that significantly impacts renal function. Despite conventional treatments, morbidity and mortality remain high, necessitating the exploration of safer and more effective therapies, including the potential benefits of Traditional Chinese Medicine (TCM) for improving kidney health and survival rates.
Methods: Patients with newly diagnosed SLE with catastrophic illness certificate were retrospectively enrolled from the Chang Gung Research Database (CGRD) between 2005 and 2020. Patients were stratified into groups based on TCM treatment post-diagnosis. Outcomes measured included end-stage renal disease (ESRD) incidence and all-cause mortality, using Cox proportional hazard models and Kaplan-Meier analysis for statistical evaluation.
Results: Among 10,462 newly diagnosed SLE patients, 1,831 had received at least 28 days of TCM treatment, while 7,966 had not received TCM treatment. After propensity score matching, there were equally 1,831 individuals in each group, with no significant baseline differences in age, sex, biochemical profiles, or comorbidities. TCM usage was associated with a significantly reduced rate of ESRD over a 0.5-year follow-up (adjusted hazard ratio (aHR) = 0.24; 95% confidence interval (CI) = 0.07-0.80, p = .02), with a trend that persisted over 5 years. The TCM group's proteinuria was significantly lower than that of the non-TCM group at various time points post-index date, including 6 months (174.98 mg vs. 248.09 mg, p <.001), 1 year (161.05 mg vs. 303.03 mg, p <.001), 3 years (150.26 mg vs. 250 mg, p = .03), and 10 years (147.06 mg vs. 190.75 mg, p = .03). After adjusting for confounding covariates, TCM users had a significantly decreased risk of mortality (aHR = 0.70, 95% CI = 0.58-0.83).
Conclusion: Integrating TCM with conventional treatment could lower risk of ESRD and mortality, highlighting the potential for a more holistic approach to patient care for SLE.
背景:系统性红斑狼疮(SLE)是一种多方面的自身免疫性疾病,严重影响肾功能。尽管采用了常规治疗方法,但发病率和死亡率仍然很高,因此需要探索更安全、更有效的治疗方法,包括中医在改善肾脏健康和生存率方面的潜在益处。方法:回顾性研究2005年至2020年CGRD新诊断的SLE伴大病证明患者。根据诊断后中医治疗情况对患者进行分组。测量的结果包括终末期肾病(ESRD)发病率和全因死亡率,使用Cox比例风险模型和Kaplan-Meier分析进行统计评价。结果在10462例新诊断SLE患者中,接受中医治疗28天以上的有1831例,未接受中医治疗的有7966例。在倾向评分匹配后,每组平均有1831人,在年龄、性别、生化特征和合并症方面没有显著的基线差异。在为期0.5年的随访中,中药使用与ESRD发生率显著降低相关(校正风险比(aHR): 0.24;95%置信区间(CI): 0.07-0.80, p = 0.02),且趋势持续5年以上。中药组在指标后6个月(174.98 mg比248.09 mg, p < 0.001)、1年(161.05 mg比303.03 mg, p < 0.001)、3年(150.26 mg比250 mg, p = 0.03)、10年(147.06 mg比190.75 mg, p = 0.03)各时间点的蛋白尿均显著低于非中药组。在调整混杂协变量后,中药使用者的死亡风险显著降低(aHR 0.70, 95% CI 0.58-0.83)。结论:中医与常规治疗相结合可以降低ESRD的风险和死亡率,强调了对SLE患者进行更全面治疗的潜力。
期刊介绍:
Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance